Open-label salsalate for the treatment of pre-diabetes in people with schizophrenia
暂无分享,去创建一个
[1] B. Kirkpatrick,et al. Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects , 2011, Biological Psychiatry.
[2] K. Jablonski,et al. The Effects of Salsalate on Glycemic Control in Patients With Type 2 Diabetes , 2010, Annals of Internal Medicine.
[3] J. Bunt,et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study , 2009, Diabetologia.
[4] Emmanuel Stip,et al. Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review , 2008, Biological Psychiatry.
[5] Sami Pirkola,et al. Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey , 2008, European Archives of Psychiatry and Clinical Neuroscience.
[6] J. Lieberman,et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls , 2005, Schizophrenia Research.
[7] S. Ghosh,et al. Inhibition of NF-kappa B by sodium salicylate and aspirin. , 1994, Science.
[8] G. Elta,et al. Gastroduodenal mucosal damage with salsalate versus aspirin: results of experimental models and endoscopic studies in humans. , 1990, Seminars in arthritis and rheumatism.
[9] R. Williamson,et al. On the Treatment of Glycosuria and Diabetes Mellitus with Sodium Salicylate , 1901, British medical journal.